Evidence map›Paper›PMID 35900175›Full record

ArticleJNCI cancer spectrum2022

Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients.

Julienne E Bower, Patricia A Ganz, Michael R Irwin, Steve W Cole, Judith Carroll, Kate R Kuhlman, Laura Petersen, Deborah Garet, Arash Asher, Sara A Hurvitz and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. The evaluation of the inflammatory status and systemic antioxidant-oxidant balance of women with breast cancer during adjuvant chemotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Julienne E BowerDepartment of Psychology, University of California, Los Angeles, CA, USA.ORCID 0000-0003-0813-4444
Patricia A GanzJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Michael R IrwinDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Steve W ColeDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Judith CarrollDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Kate R KuhlmanCousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Laura PetersenJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.ORCID 0000-0002-4843-2692
Deborah GaretCousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Arash AsherCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.
Sara A HurvitzJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Catherine M CrespiJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Salk Institute for Biological Studies · USUniversity of California, Los Angeles · USCedars-Sinai Medical Center · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Biobehavioral predictors of fatigue in newly-diagnosed breast cancer patientsR01CA160427 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOWER, JULIENNE E · 2012 to 2016
$3.2M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA160427
6 · The paper itself

Abstract

backgroundInflammation contributes to poor behavioral, functional, and clinical outcomes in cancer survivors. We examined whether standard cancer treatments-radiation and chemotherapy-led to acute and persistent changes in circulating markers of inflammation in breast cancer patients.

methodsA total of 192 women diagnosed with early stage breast cancer provided blood samples before and after completion of radiation and/or chemotherapy and at 6-, 12-, and 18-month posttreatment follow-ups. Samples were assayed for circulating inflammatory markers, including tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, downstream markers of their activity (soluble TNF receptor type II [sTNF-RII], C reactive protein), and other inflammatory mediators (IL-8, interferon-γ [IFN-γ]). Analyses evaluated within-group changes in inflammatory markers in 4 treatment groups: no radiation or chemotherapy (n = 39), radiation only (n = 77), chemotherapy only (n = 18), and chemotherapy with radiation (n = 58).

resultsPatients treated with chemotherapy showed statistically significant increases in circulating concentrations of TNF-α, sTNF-RII, IL-6, and IFN-γ from pre- to posttreatment, with parameter estimates in standard deviation units ranging from 0.55 to 1.20. Those who received chemotherapy with radiation also showed statistically significant increases in IL-8 over this period. Statistically significant increases in TNF-α, sTNF-RII, IL-6, IFN-γ, and IL-8 persisted at 6, 12, and 18 months posttreatment among patients treated with chemotherapy and radiation (all P < .05). Patients treated with radiation only showed a statistically significant increase in IL-8 at 18 months posttreatment; no increases in any markers were observed in patients treated with surgery only.

conclusionsChemotherapy is associated with acute increases in systemic inflammation that persist for months after treatment completion in patients who also receive radiation therapy. These increases may contribute to common behavioral symptoms and other comorbidities in cancer survivors.

Indexed as

Inflammatory Breast NeoplasmsReceptors, Tumor Necrosis FactorBiomarkersFemaleHumansInflammationInterferon-gammaInterleukin-6Interleukin-8Tumor Necrosis Factor-alphaBiomarkersInterferon-gammaInterleukin-6Interleukin-8Receptors, Tumor Necrosis FactorTumor Necrosis Factor-alpha

Identifiers

PMID35900175
PMCPMC9420043
OpenAlexW4288436683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.